TipRanks
Alkermes (ALKS)
NASDAQ:ALKS
US Market
ALKS
Alkermes
RESEARCH TOOLSreports
Want to see ALKS full AI Analyst Report?

Alkermes (ALKS) Stock News & Sentiment

636 Followers
Alkermes: Orexin Franchise Proof-of-Concept Supports Balanced Risk-Reward; Hold Rating Reiterated with Unchanged $43 Price Target
Premium
Ratings
Alkermes: Orexin Franchise Proof-of-Concept Supports Balanced Risk-Reward; Hold Rating Reiterated with Unchanged $43 Price Target
4h ago
ALKS
Alkermes: Orexin Agonism in ADHD Shows Early Promise; Buy Rating Reiterated with Unchanged $62 Price Target
Premium
Ratings
Alkermes: Orexin Agonism in ADHD Shows Early Promise; Buy Rating Reiterated with Unchanged $62 Price Target
6h ago
ALKS
Alkermes Reports Positive Phase 1 ADHD Study Results
Premium
Company Announcements
Alkermes Reports Positive Phase 1 ADHD Study Results
9h ago
8K
ALKS
Alkermes Strengthens Board with New Director Appointment
Premium
Company Announcements
Alkermes Strengthens Board with New Director Appointment
5d ago
8K
ALKS
Alkermes Amends Credit Agreement to Lower Borrowing Costs
Premium
Company Announcements
Alkermes Amends Credit Agreement to Lower Borrowing Costs
1M ago
8K
ALKS
Alkermes Earnings Call Highlights Orexin-Fueled Growth
Premium
Company Announcements
Alkermes Earnings Call Highlights Orexin-Fueled Growth
2M ago
ALKS
Alkermes: Solid Q2 and Promising Orexin-2 Pipeline, But Execution Risks Keep Rating at Hold and Price Target Unchanged at $43
Premium
Ratings
Alkermes: Solid Q2 and Promising Orexin-2 Pipeline, But Execution Risks Keep Rating at Hold and Price Target Unchanged at $43
2M ago
ALKS
More ALKS News >

ALKS News on the Web

Alkermes announces Phase 1b results of ALKS 7290 in ADHD
TipRanks News
Bullish
Congress Trade: Representative Gilbert Ray Cisneros, Jr. Just Disclosed New Stock Trades
Quiver Quantitative
Neutral
Alkermes (ALKS) EVP and CLO David Gaffin Sells 2,034 Shares
GuruFocus News
Neutral
Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000
The Motley Fool
Bullish
Alkermes’ alixorexton featured in published Phase 2 study of narcolepsy
TipRanks News
Bullish
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
Zacks
Neutral
Should Investors Buy INDV as Sublocade Growth Meets Rising Risks?
Zacks
Neutral
Alkermes Stock Sinks As Earnings Jolt Investors
TipRanks News
Neutral

News Score - Last 7 Days

Positive
ALKS
Sector Average
Media Buzz
This Week4 articles
Weekly Average2.75 articles
News Sentiment
This Week100%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is ALKS’s Media Buzz Sentiment?
4 articles about ALKS were published this week. In an average week, 2.75 articles are published.
    What is ALKS’s weekly average amount of articles?
    In an average week, 2.75 articles about ALKS are published.
      What is ALKS’s News Sentiment?
      100% of articles about ALKS were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        CRLCharles River Labs
        DFTXDefinium Therapeutics
        AMRXAmneal Pharmaceuticals
        IOVAIovance Biotherapeutics
        HITIHigh Tide
        Showing the stocks with the most bullish news sentiment over the past week